Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemoradiotherapy Followed by Surgery and Consolidation Chemotherapy for Stage III NSCLC
NCT00096226Phase 2Completed
- Sponsor
- NRG Oncology
- Start
- Sep 2004
- Primary completion
- Apr 2012
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and carboplatin in non-small cell lung cancer (NSCLC), sponsored by NRG Oncology. Primary endpoint: Mediastinal Nodal Clearance Rate at 14 weeks. Started Sep 2004; status: completed.
02
Drugs
paclitaxelcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00096226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00096226.